Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease.

Cluster of differentiation 20 (CD20) is an integral membrane protein expressed mainly on different developmental stages of B lymphocytes and rarely on T lymphocytes, and it functions as a link to B cell antigen receptor (BCR) and immune microenvironment via regulating calcium ion influx, cell cycle progression and interaction between isotypic BCRs and their co-receptors. Diverse therapeutic monoclonal antibodies (mAbs) targeting CD20 are generated and grouped into two types based on the ability to redistribute CD20 into lipid rafts, which results in huge differences in response. Currently, multiple anti-CD20 mAbs have been approved as drugs for neurological and neuromuscular diseases with promising clinical efficacy. This review aims to summarize the potential mechanisms, development and current evidence for anti-CD20 therapy in neurological and neuromuscular diseases.

• Publication year

  2022

• Venue

  Pharmacology and Therapeutics

• Publication date

  2022-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2022.108180PMID 35367516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study

  2021cited by this paper
• Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis

  2021cited by this paper
• Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management

  2021cited by this paper
• Neuronal Surface Antibody-Medicated Autoimmune Encephalitis (Limbic Encephalitis) in China: A Multiple-Center, Retrospective Study

  2021cited by this paper
• Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.

  2021cited by this paper
• Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis

  2021cited by this paper
• Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

  2021cited by this paper
• Rituximab for the treatment of multiple sclerosis: a review

  2021cited by this paper
• Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials

  2021cited by this paper
• Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.

  2021cited by this paper
• Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis

  2021cited by this paper
• Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis

  2021cited by this paper
• Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis

  2021cited by this paper
• Anti-CD20 therapies for multiple sclerosis: current status and future perspectives

  2021cited by this paper
• Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis

  2021cited by this paper
• Autoantibodies in neurological disease

  2021cited by this paper
• Rituximab Treatment in Acute Disseminated Encephalomyelitis Associated with Salmonella Infection

  2021cited by this paper
• Idiopathic inflammatory myopathies

  2021cited by this paper
• Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera

  2020cited by this paper
• Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

  2020cited by this paper
• Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis

  2020cited by this paper
• Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti‐rituximab antibodies

  2020cited by this paper
• Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice.

  2020cited by this paper
• Binding mechanisms of therapeutic antibodies to human CD20

  2020cited by this paper
• CD20 as a gatekeeper of the resting state of human B cells

  2020cited by this paper
• Ofatumumab versus Teriflunomide in Multiple Sclerosis.

  2020cited by this paper
• Rituximab in refractory chronic inflammatory demyelinating polyneuropathy

  2020cited by this paper
• Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis

  2020cited by this paper
• Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

  2020cited by this paper
• Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

  2020cited by this paper
• Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features

  2020cited by this paper
• Ocrelizumab initiation in patients with MS

  2020cited by this paper
• A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

  2020cited by this paper
• The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy

  2020cited by this paper
• Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis

  2020cited by this paper
• Myasthenia gravis.

  2020cited by this paper
• Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.

  2020cited by this paper
• Targeting B Cells to Modify MS, NMOSD, and MOGAD

  2020cited by this paper
• New therapies for neuromyelitis optica spectrum disorder.

  2020cited by this paper
• Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.

  2020cited by this paper
• Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents

  2020cited by this paper
• [Idiopathic inflammatory myopathies].

  2019cited by this paper
• Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

  2019cited by this paper
• B-Cell Therapies in Multiple Sclerosis.

  2019cited by this paper
• Refractory myasthenia gravis successfully treated with ofatumumab

  2019cited by this paper
• A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma

  2019cited by this paper
• Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab

  2019cited by this paper
• Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder

  2019cited by this paper
• A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder

  2019cited by this paper
• Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.

  2019cited by this paper
• Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy

  2018cited by this paper
• Risk factors and disease mechanisms in myositis

  2018cited by this paper
• Multiple Sclerosis

  2018cited by this paper
• The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells

  2018cited by this paper
• Antibody-Mediated Encephalitis.

  2018cited by this paper
• Necrosis in anti-SRP+ and anti-HMGCR+myopathies

  2018cited by this paper
• Multiple sclerosis

  2018cited by this paper
• Multiple Sclerosis Pathology.

  2018cited by this paper
• Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

  2018cited by this paper
• Immunotherapy in myasthenia gravis in the era of biologics

  2018cited by this paper
• Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis

  2018cited by this paper
• Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis

  2018cited by this paper
• Biologics for idiopathic inflammatory myopathies

  2017cited by this paper
• Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

  2017cited by this paper
• NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody

  2017cited by this paper
• Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab

  2017cited by this paper
• The Use of Rituximab in the Management of Refractory Dermatomyositis.

  2017cited by this paper
• Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations.

  2017cited by this paper
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

  2017cited by this paper
• Rituximab as treatment for anti-MuSK myasthenia gravis

  2017cited by this paper
• A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

  2017cited by this paper
• Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

  2017cited by this paper
• Rituximab in the treatment of inflammatory myopathies: a review.

  2017cited by this paper
• Genentech's Ocrevus heralds new chapter in MS treatment

  2017cited by this paper
• Myasthenia gravis — autoantibody characteristics and their implications for therapy

  2016cited by this paper
• Rituximab in multiple sclerosis

  2016cited by this paper
• Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort

  2016cited by this paper
• The MS4A family: counting past 1, 2 and 3

  2016cited by this paper
• Features of Human CD3+CD20+ T Cells

  2016cited by this paper
• Myasthenia Gravis.

  2016cited by this paper
• Immunopathology of multiple sclerosis

  2015cited by this paper
• Pathological mechanisms in progressive multiple sclerosis.

  2015cited by this paper
• Inflammatory Muscle Diseases.

  2015cited by this paper
• Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

  2015cited by this paper
• Myasthenia gravis: subgroup classification and therapeutic strategies

  2015cited by this paper
• Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

  2014cited by this paper
• Diagnosis and treatment of chronic acquired demyelinating polyneuropathies

  2014cited by this paper
• Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

  2014cited by this paper
• Abnormal neurons in teratomas in NMDAR encephalitis.

  2014cited by this paper
• Obinutuzumab: a new class of anti-CD20 monoclonal antibody

  2014cited by this paper
• B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk

  2014cited by this paper
• Role of the blood-brain barrier in multiple sclerosis.

  2014cited by this paper
• Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

  2013cited by this paper
• CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes

  2013cited by this paper
• Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

  2013cited by this paper
• Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

  2013cited by this paper
• Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity*

  2012cited by this paper
• Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

  2011cited by this paper
• Review: An update on inflammatory and autoimmune myopathies

  2011cited by this paper
• Advances in the diagnosis, pathogenesis and treatment of CIDP

  2011cited by this paper

• BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares

  2026cites this paper
• A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration's adverse event reporting system databases.

  2026cites this paper
• Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis

  2025cites this paper
• Treatment and prognosis of failure of first-line immunotherapy or recurrent autoimmune encephalitis patients with ofatumumab—a fully human anti-CD20 mAb

  2025cites this paper
• Chimeric antigen receptor T cell therapy: a new frontier therapeutic landscape in autoimmune diseases.

  2025cites this paper
• An angel or a devil? Current view on the role of CD8+ T cells in the pathogenesis of myasthenia gravis

  2024cites this paper
• Targeted Therapy for SLE—What Works, What Doesn’t, What’s Next

  2023cites this paper
• Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis

  2022cites this paper
• Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies

  2022cites this paper